Table 3. Analysis for overall survival and recurrence-free survival using the univariate and multivariate Cox proportional hazards regression model for BCLC stage 0-A HCC in the validation cohort.
| Variables | Overall survival | Recurrence-free survival | ||||||
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| Age | 0.999(0.983-1.015) | 0.902 | 1.006(0.990-1.022) | 0.496 | ||||
| Gender (F/M) | 0.831(0.477-1.447) | 0.513 | 0.633(0.352-1.138) | 0.126 | ||||
| HBsAg (+/-) | 1.959(0.905-4.239) | 0.088 | 1.148(0.612-2.153) | 0.668 | ||||
| HBV DNA (>105/103-105/0) | 1.586(1.212-2.075) | 0.001 | 1.521(1.156-2.001) | 0.003 | 1.206(0.932-1.560) | 0.154 | ||
| Cirrhosis (+/-) | 1.073(0.704-1.638) | 0.742 | 0.899(0.594-1.360) | 0.614 | ||||
| Portal hypertension (+/-) | 0.705(0.365-1.362) | 0.298 | 1.197(0.689-2.080) | 0.522 | ||||
| Ascites (+/-) | 1.497(0.846-2.648) | 0.166 | 2.504(1.455-4.310) | 0.001 | 2.550(1.452-4.480) | 0.001 | ||
| AFP (≥400/<400) | 1.156(0.762-1.753) | 0.496 | 1.501(0.998-2.256) | 0.051 | ||||
| Tumor size (≥5/<5) | 2.070(1.350-3.175) | 0.001 | 1.900(1.220-2.959) | 0.005 | 1.808(1.193-2.740) | 0.005 | 1.615(1.052-2.480) | 0.028 |
| Differentiation (Poor /Well-Moderate) | 1.509(1.002-2.274) | 0.049 | 1.426(0.941-2.161) | 0.094 | 1.421(0.947-2.132) | 0.090 | ||
| Microvascular invasion | 1.742(1.139-2.665) | 0.011 | 1.372(0.882-2.134) | 0.161 | 2.048(1.353-3.101) | 0.001 | 1.690(1.099-2.599) | 0.017 |
| TLS (+/-) | 0.742(0.472-1.167) | 0.196 | 0.534(0.334-0.855) | 0.008 | 0.524(0.326-0.482) | 0.008 | ||
F: female; M: male; HBV: hepatitis B virus; HCV: hepatitis V virus; AFP: alpha-fetoprotein; BCLC: Barcelona Clinic of Liver Cancer; TLS: tertiary lymphoid structures; HR, hazard ratio; CI, confidence interval.